Infantile Neuroaxonal Dystrophy

ViTAA Medical Secures FDA 510(k) Clearance for AiORTA Plan, Launching Its Hyper-Precise Aortic Care Platform

1 month ago talkbio0Tagged AiORTA, Anatomical segmentation, Aortic Aneurysm, automated aortic surgery, Clearance, Clinical, cloud-based healthcare, hyper-precise aortic care, Infantile Neuroaxonal Dystrophy, measurement automation, Medical service, Preoperative, United States Food and Drug Administration, vascular AI, ViTAA, workflow improvement

ViTAA Medical; FDA 510(k) clearance; AiORTA Plan; hyper-precise aortic care; automated aortic surgery planning; vascular AI; preoperative measurement automation; cloud-based healthcare; aortic aneurysm segmentation; clinical workflow improvement

Roche could rethink $50B US expansion plan if new policies ‘harm’ operations

7 months ago talkbio0Tagged expansion, Infantile Neuroaxonal Dystrophy, Investments, Policy, Roche (company), United States

Roche (company), United States, Investments, expansion, Policy, Infantile Neuroaxonal Dystrophy

Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth

8 months ago talkbio0Tagged biopharmaceutical sector, Biotechnology, Clinical Trials, Corporate, financial, Infantile Neuroaxonal Dystrophy, Investments, restructuring, stockholder, strategic alternatives

Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments

Johnson & Johnson Boosts Talc Settlement by $1.1 Billion Amid Ongoing Negotiations

1 year ago talkbio0Tagged Bankruptcy, Increase, Infantile Neuroaxonal Dystrophy, Johnson and Johnson, Talc Settlement

Johnson & Johnson, Talc Settlement, $1.1 Billion Increase, Cancer Lawsuits, Bankruptcy Plan